N/A N=401 Real-Life Passive Exposure Assessment of IQOS
Environmental Exposure
Primary: NEQ: (Non-Exposure Event) — 0.03845; 4.159; 5.695; 0.06876 mg/g
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=174 Evaluation of Safety and Efficacy of rhNGF in Patients With Stage 2 and 3 Neurotrophic Keratitis.
Neurotrophic Keratitis · Keratitis · Corneal Ulcer
Primary: Percentage of Patients Achieving Healing of the Persistent Epithelial Defect (PED) or Corneal Ulcer — 55; 58; 20; 45 percentage of subjects — p=<0.001
Phase 4 N=55 A Phase 4 Post-marketing Study of Intramuscular Injections of BLB-750 in Healthy Adult Subjects
Pandemic Influenza Prevention
Primary: Seroprotection Rate as Measured by Single Radial Hemolysis (SRH) Antibody Titer for the Vaccine Strain at 21 Days After the Second Vaccination — 32.7 Percentage of…
Phase 2 N=61 Effectiveness Study of Dronabinol and BRENDA for the Treatment of Cannabis Withdrawal
Marijuana Dependence
Primary: Physiological Changes in Response to Cue-induced Craving. — 5.65 T value
Phase 1 N=26 Palbociclib Pharmacokinetics Study In Postmenopausal Chinese Women With ER (+), HER2 (-) Advanced Breast Cancer
Advanced Breast Cancer
Primary: Single-dose Pharmacokinetics (PK): Maximum Plasma Concentration (Cmax) for Palbociclib — 82.14 nanograms per milliliter (ng/mL)
Phase 2 N=300 Study of ChimeriVax™ Tetravalent Dengue Vaccine in Healthy Peruvian Children Aged 2 to 11 Years
Dengue Virus · Dengue Fever · Dengue Hemorrhagic Fever
Primary: Percentage of Participants (Aged 2 to 11 Years) Reporting Solicited Injection-site and Systemic Reactions Following Each Injection (Inj.) With CYD Dengue Vaccine or…
Phase 3 N=624 Study of a Booster Injection of Pentaxim™ Vaccine Administered With Dengue Vaccine in Healthy Toddlers
Dengue · Dengue Hemorrhagic Fever
Primary: Percentage of Participants With Seroprotection or Booster Response After a Booster Injection (Inj.) of Diphtheria, Tetanus, Acellular Pertussis(DTaP)-Inactivated Polio…
Phase 3 N=436 A Phase III Study of NK105 in Patients With Breast Cancer
Breast Cancer Nos Metastatic Recurrent
Primary: Progression Free Survival — 8.4; 8.5 months
N/A N=118 diEtitiaNs Helping pAtieNts CarE for Diabetes (ENHANCED)
Diabetes Mellitus, Type 2
Primary: A1c (Laboratory Assessment) — 35; 35 Participants
Phase 3 N=211 Etanercept (Enbrel®) in Psoriasis - Pediatrics
Psoriasis
Primary: Percentage of Participants Achieving a ≥ 75% Improvement in Psoriasis Area and Severity Index Score (PASI 75) at Week 12 — 11.0; 57.0 percentage of participants…
N/A N=64 Oral Contraceptive Hormone-free Interval Pituitary/ Ovarian Activity
Hypothalamic-pituitary-ovarian Axis, Gonadotropins, Ethinyl Estradiol, Contraceptive Efficacy
Primary: Follicle-stimulating Hormone — 5.01; 5.86; 6.38 milli international units per milliliter — p=0.88
Phase 1 N=61 Methodology Study To Examine 6-Week Food Intake With Liraglutide In Obese Subjects
Obesity
Primary: Change From Baseline (Visit 3) in Mean Energy Intake During Ad Libitum Lunches at Visits 4 and 5 — -254.48; -19.93; -278.78; -37.43 kilocalories (kcal) — p=0.0000
N/A N=52 MRI Study of Changes in Blood-Brain/Tumor-Barrier Permeability in Patients With Brain Metastases During and After Radiotherapy
Brain Metastases
Primary: Percentage of the Gross Tumor Volume With a BTB Opening of Ktrans > 0.005 Min-1 — 78.6; 85.6; 6.4; 74.4 percentage of gross tumor volume
Phase 2 N=10 Eltrombopag in Combination With Rabbit Anti-thymocyte Globulin/Cyclosporine A in Naive Aplastic Anemia (AA) Subjects
Aplastic Anemia
Primary: ORR at 6 Months: Overall Response Rate (ORR) Defined as the Number of Participants Who Met the Criteria of Either Complete Response (CR) or Partial Response (PR) at Week…
Phase 3 N=206 Extension Study of Liposomal Amikacin for Inhalation in Cystic Fibrosis (CF) Patients With Chronic Pseudomonas Aeruginosa (Pa) Infection
Cystic Fibrosis
Primary: Treatment Emergent Adverse Events (TEAEs) up to Day 672 — 183; 92; 21 Participants